Macroamylasemia — a rare variant of hyperamylasemia in pediatric practice
- Authors: Drozdova S.N.1, Kornienko E.A.1, Moiseikova E.L.1
-
Affiliations:
- Saint Petersburg State Pediatric Medical University
- Issue: Vol 15, No 4 (2024)
- Pages: 85-91
- Section: Clinical observation
- URL: https://journal-vniispk.ru/pediatr/article/view/279242
- DOI: https://doi.org/10.17816/PED15485-91
- ID: 279242
Cite item
Abstract
Macroamylasemia is a rare disorder characterized by the formation of an amylase-globulin complex that is too large to be easily cleared by the kidneys, resulting in elevated serum amylase levels. It is a benign condition with no serious signs or symptoms and requires no treatment. This article presents a case of long-term asymptomatic hyperamylasemia in a 10-year-old child. The child was admitted to the gastroenterology department with complaints of abdominal pain. Since the age of 8, there have been unexplained increases in serum amylase to 235 U/L and pancreatic amylase to 63.5 U/L, without clinical manifestations of pancreatitis, with normal levels of urine amylase and coprological elastase. An examination was performed, during which pancreatic pathology was excluded. The ratio of amylase and creatinine clearances was 0.754%. This ratio turned out to be less than 1%, which is more likely to indicate macroamysalemia. After further examination, type 1 macroamylasemia was diagnosed, which was the cause of hyperamylasemia — a non-life-threatening biochemical anomaly that requires a detailed examination, broad differential diagnostics, but does not require treatment. However, macroamylasemia is a diagnostic challenge because it must be differentiated from other causes of hyperamylasemia to avoid unnecessary testing and treatment. Hyperamylasemia is one of the main diagnostic criteria for pancreatitis, requiring extensive additional testing and treatment, often in a hospital setting. Therefore, it is important that physicians can recognize and diagnose macroamylasemia at an early stage to avoid unnecessary diagnostic and therapeutic measures. In this regard, we hope that the clinical example we have provided will be interesting and useful for physicians of various specialties.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Svetlana N. Drozdova
Saint Petersburg State Pediatric Medical University
Author for correspondence.
Email: s.drozdova@mail.ru
ORCID iD: 0009-0009-2163-4778
SPIN-code: 9129-4393
MD, PhD, Associate Professor, Department of Pediatrics named after Professor I.M. Vorontsov at the Faculty of Postgraduate and Additional Professional Education
Russian Federation, 2 Litovskaya st., Saint Petersburg, 194100Elena A. Kornienko
Saint Petersburg State Pediatric Medical University
Email: elenkornienk@yandex.ru
ORCID iD: 0000-0003-2743-1460
SPIN-code: 5120-9007
MD, PhD, Dr. Sci. (Medicine), Professor, Department of Pediatrics named after Professor I.M. Vorontsov at the Faculty of Postgraduate and Additional Professional Education
Russian Federation, 2 Litovskaya st., Saint Petersburg, 194100Ekaterina L. Moiseikova
Saint Petersburg State Pediatric Medical University
Email: igumenjva@mail.ru
ORCID iD: 0009-0000-5043-8965
SPIN-code: 6581-9294
MD, PhD, Associate Professor, Department of Pediatrics named after Professor I.M. Vorontsov at the Faculty of Postgraduate and Additional Professional Education
Russian Federation, 2 Litovskaya st., Saint Petersburg, 194100References
- Vorontsov IM, Mazurin AV. Propedeutics of pediatric diseases. 3rd edit. Saint Petersburg: Foliant; 2009. (In Russ.)
- Gubergrits NB, Byelyayeva NV, Lukashevich GM, Mozhyna TL. Secrets, puzzles and mysteries of macroamylasemia. Bulletin of the Pancreatology Club. 2020;(1):12–22. EDN: IVMAIZ
- Minina SN, Kornienko EA, Suspitsyn ЕN, Imyanitov EN. The etiological structure, diagnostic criteria and principles of treatment of pancreatitis in children. Pediatric Nutrition. 2020;18(3):54–64. EDN: JAVOQV doi: 10.20953/1727-5784-2020-3-54-64
- Nikolskaya KA, Bordin DS, Vinokurova LV, et al. Hyperamylasemia — is it always pancreatitis? Farmateka. 2019;(2):130–135. EDN: VVYXEQ doi: 10.18565/pharmateca.2019.2.130-35
- Yagupova AA, Kornienko EA, Loboda TB, Fadina SA. New diagnosis in pediatric practice: autoimmune pancreatitis. Pediatrician (St. Petersburg). 2013;4(4):48–55. EDN: QFLZEA doi: 10.17816/PED4448-55
- Depsames R, Fireman Z, Niv E, Kopelman Y. Macroamylasemia as the first manifestation of celiac disease. Case Rep Gastroenterol. 2008;2(2):196–198. doi: 10.1159/000132771
- Fujimura Y, Nishishita C, Uchida J, Iida M. Macroamylasemia associated with ulcerative colitis. J Mol Med (Berl). 1995;73:95–97. doi: 10.1007/BF00270584
- Gallucci F, Buono R, Ferrara L, et al. Chronic asymptomatic hyperamylasemia unrelated to pancreatic diseases. Adv Med Sci. 2010;55(2):143–145. doi: 10.2478/v10039-010-0049-9
- Joksimovic Z, Bastac D, Pavlovic S. Macroamylasemia as a cause of hyperamylasemia in clinically unclear conditions: case report. Timoc Med Glas. 2020;45(1–2):68–72. doi: 10.5937/tmg2001068J
- Lam R, Muniraj T. Hyperamylasemia. Treasure Island (FL): StatPearls Publishing; 2021.
- Šimac DV, Špelić M. Using polyethylene glycol precipitation to confirm macroamylasemia. Acta Med Croatica. 2020;74(3):293–294.
- Simac DV, Spelic M, Devcic B, Racki S. Diagnosing macroamylasemia in unexplained hyperamylasemia. Acta Med Croatica. 2017;71(1):63–66.
- Tseng Y, Luo Z, Zhang H, et al. Asymptomatic hyperamylasemia in Stevens-Johnson syndrome is associated with intestinal barrier dysfunction. Biomed Res Int. 2020;2020:3531907. doi: 10.1155/2020/3531907
Supplementary files
